Antibodies directed to the deletion mutants of epidermal...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) C07K 16/28 (2006.01) C07K 17/00 (2006.01)

Patent

CA 2530285

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

La présente invention se rapporte à de nouveaux anticorps, notamment à des anticorps dirigés contre les mutants de délétion du récepteur du facteur de croissance épidermique, et notamment le mutant de délétion de type III, EGFRvIII. L'invention se rapporte également à des anticorps monoclonaux humains dirigés contre les mutants de délétion du récepteur du facteur de croissance épidermique, notamment EGFRvIII. L'invention se rapporte en outre à des formulations diagnostiques et thérapeutiques de ces anticorps, et d'immunoconjugués de ces anticorps.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies directed to the deletion mutants of epidermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies directed to the deletion mutants of epidermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed to the deletion mutants of epidermal... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1772072

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.